DelveInsight’s, “Epilepsy Pipeline Insight 2024” report provides comprehensive insights about 85+ companies and 90+ pipeline drugs in Epilepsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our comprehensive Epilepsy Pipeline Report to stay informed about the latest advancements. Download copy now @ Epilepsy Pipeline Outlook
Key Takeaways from the Epilepsy Pipeline Report
- In September 2024:- Ono Pharmaceuticals- A Phase 2, Multicenter Open-Label Extension Study to Evaluate the Long-term Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures. To evaluate the long-term safety and tolerability of cenobamate in Japanese epilepsy patients with partial seizures.
- In September 2024:- UCB Biopharma SRL- The purpose of the study is to investigate the long-term safety and tolerability of brivaracetam in study participants with childhood absence epilepsy or juvenile absence epilepsy.
- In September 2024:- Biohaven Therapeutics Inc.- A Phase 2/3 Multicenter, Randomization, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy. The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
- DelveInsight’s Epilepsy pipeline report depicts a robust space with 85+ active players working to develop 90+ pipeline therapies for Epilepsy treatment.
- The leading Epilepsy Companies such as UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics, and others.
- Promising Epilepsy Therapies such as Lorcaserin, Cenobamate, SPN-817, EQU-001, Diazepam Nasal Spray, Brivaracetam, Cannabidiol, Lacosamide, Perampanel, and others.
Dive into our Epilepsy Pipeline Report to uncover promising therapies and breakthroughs. Gain insights that could shape the future of oncology @ Epilepsy Treatment Therapies
Epilepsy Emerging Drugs
- XEN1101: Xenon Pharmaceuticals
XEN1101 is a novel, small-molecule, selective Kv7.2/Kv7.3 potassium channel opener being developed for the treatment of focal epilepsy. Its mechanism of action involves positively modulating these specific voltage-gated potassium channels, which leads to increased potassium ion flow out of neurons, resulting in neuronal hyperpolarization and reduced neuronal excitability this effect helps to decrease the likelihood of seizures occurring. XEN1101 is primarily metabolized by cytochrome P450 3A4 (CYP3A4) without substantial involvement of other CYPs, and plasma levels of XEN1101 may decrease in the presence of CYP3A4 inducers. The route of administration of this drug is oral. Currently, the drug is in the Phase III stage of its clinical trial for the treatment of epilepsy.
- EPX-100: Epygenix Therapeutics
EPX-100 is a potential new treatment being developed by Epygenix Therapeutics for people with Dravet syndrome. Dravet syndrome is a rare and severe form of epilepsy characterized by prolonged seizures, often happening numerous times each day. It is known that the disease is caused by a mutation in the SCN1A gene, but it is not fully understood how this mutation leads to the development of seizures. EPX-100 is a repurposed antihistamine, which was used in the 1950s and 1960s to treat itchiness. The medication is thought to be able to suppress seizures through its action on the serotonin signaling pathways, a mechanism that is different from its anti-histaminic properties. Currently, the drug is in the Phase II stage of its clinical trial for the treatment of epilepsy.
- Darigabat: Cerevel Therapeutics
Darigabat, formerly CVL-865, is a subtype selective positive allosteric modulator that targets GABAA receptors containing α2/3/5 subunits. It is structurally differentiated from classical benzodiazepines and minimizes activity at α1-containing receptors, which is believed to help mitigate many of the adverse events associated with benzodiazepines. Currently, the drug is in the Phase II stage of its clinical trial for the treatment of epilepsy.
- TRV-045: Trevena
Trevena is currently developing a novel, selective sphingosine-1-phosphate subtype 1 receptor (S1P1R) modulator, TRV045, as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. Through a collaboration with the National Institutes of Health, Trevena is also exploring TRV045 as a potential treatment for epilepsy. Currently, the drug is in the Phase I stage of its clinical trial for the treatment of epilepsy.
- OV-350: Ovid Therapeutics
OV-350 is an investigational drug being developed by Ovid therapeutics. The KCC2 transporter is a neuron-specific chloride extruder that is critical for maintaining GABA’s inhibitory function in the mature brain. Deficits in KCC2 activity have been associated with epilepsy and other neuropathological disorders. OV350 directly activates KCC2, thereby restoring chloride homeostasis in neurons and subsequently reducing hyperexcitability. The drug is currently in the preclinical stage of development for the treatment of patients with Epilepsy.
Download the Epilepsy Pipeline Report to discover partnership opportunities and collaborate in driving impactful solutions forward @ Epilepsy Clinical Trials Assessment
Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
Epilepsy Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
Dive into our detailed Epilepsy Pipeline Report to discover groundbreaking advancements shaping the future of cancer treatment @ Epilepsy Products, Companies, and Unmet Needs
Scope of the Epilepsy Pipeline Report
- Coverage- Global
- Epilepsy Companies- UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics, and others.
- Epilepsy Therapies- Lorcaserin, Cenobamate, SPN-817, EQU-001, Diazepam Nasal Spray, Brivaracetam, Cannabidiol, Lacosamide, Perampanel, and others.
- Epilepsy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Epilepsy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Gain valuable insights into emerging therapies and innovations with our Epilepsy Pipeline Report @ Epilepsy Market Drivers and Barriers, Future Perspectives and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Epilepsy: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Epilepsy– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- ZX008 (Fenfluramine Hydrochloride): UCB
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- STK-001: Stoke Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- BMB-101: Bright Minds Biosciences
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- NT102: Neuroene Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Epilepsy Key Companies
- Epilepsy Key Products
- Epilepsy- Unmet Needs
- Epilepsy- Market Drivers and Barriers
- Epilepsy- Future Perspectives and Conclusion
- Epilepsy Analyst Views
- Epilepsy Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Epilepsy Pipeline Insights, Clinical Trials, Treatment Drugs, and Companies 2024